TMCnet News
Fortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Lindsay A. Rosenwald, M.D., Fortress Biotech’s Chairman, President and CEO, will present a company update at PIONEERS 2017, presented by Joseph Gunnar & Co., on Tuesday, May 2, 2017 at 3:00 p.m. ET. The conference will be held at the Mandarin Oriental Hotel in New York City. A copy of the presentation will be available on the Events & Webcasts page of the Investors section of Fortress’ website: www.fortressbiotech.com. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ:NHLD), a diversified independent brokerage company (together with its sbsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com. Forward-Looking Statements
Contacts: Lucy Lu, M.D., Executive Vice President & Chief Financial Officer Fortress Biotech, Inc. 781-652-4500; [email protected] Fortress Biotech Media Relations Laura Bagby 6 Degrees (312) 448-8098; [email protected] |